News

We are thrilled this morning to announce that we are commercially launching the Curate Cell Processing System at the Phacilitate Advanced Therapies Week, one of the leading conferences for the cell and gene therapy industry.

Former Oxford Biomedica CCO to bring extensive cell and gene therapy commercialization expertise

Curate Biosciences announced that Mayo Pujols, Chief Technical Officer of late-stage gene therapy biotech Rocket Pharmaceuticals, has been appointed to its Board of Directors.

A rebranding of biopharmaceutical manufacturing as a career, and a rethink of the educational programs that feed the field, could help address a growing talent crunch.

Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Daniel Getts, Ph.D., cofounder and CEO of Myeloid Therapeutics, has been appointed to its Board of Directors. Dr. Getts is an immunologist by training and a serial entrepreneur with a proven track record in building and financing companies focused on creating next-generation immunotherapies.

To capture more T cells for such autologous cell therapy, City of Hope—one of the largest cancer research and treatment organizations in the U.S.—plans to integrate the Curate CELL PROCESSING SYSTEM into its workflow to manufacture investigational CAR-T cell immunotherapy. This system takes a new approach to T-cell separation.

City of Hope, one of the largest cancer research and treatment organizations in the US, has given a thumbs up to the Curate Biosciences' cell processing system for advanced cell separation. Having evaluated the platform, the Beckman Research Institute of City of Hope now plans to integrate the technology into its workflow to manufacture investigational CAR-T cell immunotherapy.

Curate Biosciences, a key enabling technology company for cell therapy manufacturing, announced the first outcome of its Technology Access Program, which is dedicated to converting research into real-world treatments and cures as rapidly as possible. City of Hope, one of the largest cancer research and treatment organizations in the United States, has evaluated the Curate® Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR-T cell immunotherapy.

GPB Scientific is now known as Curate Biosciences, a name it says reflects more the work it is doing for cell and gene therapy providers.
The company has spent six years working on a platform focused on cell potency and recovery; it says it has cracked one of the biggest problems in cell therapy; extracting enough potent cells to treat chronically sick patients.

GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system’s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry.

GPB Scientific, Inc., a key enabling technology company for cell therapy manufacturing, announced the hiring of Gaurav Vij and Joan Haab, PhD, as it prepares to make cell therapy available to the largest number of patients. Mr. Vij will serve as the company’s first Chief Business Officer, and Dr. Haab as its first Senior Vice President, Manufacturing and Supply Chain Operations, key positions for driving GPB’s growth as it moves to expand patient access to life-saving cell therapies…

GPB Scientific, Inc., a developer of transformative cell processing technology for next generation cell and gene therapies, today announced raising an additional $18 million in capital as part of a previously announced financing, including commitments from existing investors Vensana Capital and Amgen Ventures, and from a new undisclosed healthcare investor. This financing will support expanded placements of GPB’s Curate® Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platform’s utility in additional types of cell and gene therapy applications…

GPB Scientific, Inc., a developer of breakthrough technologies for therapeutic cell production and bioprocessing, today announced a $25.5 million funding commitment. The financing is led by Vensana Capital alongside strategic investor Amgen Ventures with ongoing participation by existing investors…

GPB Scientific LLC announced that the NIH completed its review or its achievement of Phase I milestones and authorized Phase II funding under a $2.2M NIH STTR Award. The award by the National Cancer Institute of the National Institutes of Health supports work by GPB Scientific, in collaboration with the University of Maryland School of Medicine and Princeton University, to scale up GPB Scientific’s microfluidic cell separation technology. GPB Scientific’s innovation displaces current centrifuge-based systems for selecting cells, such as isolating a patient’s own white blood cells from red cells and platelets to manufacture ground-breaking CAR-T cancer therapies…